Sector News

Biogen appoints Michel Vounatsos Executive VP, Chief Commercial Officer

March 31, 2016
Life sciences

Biogen today announced the appointment of Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016.

Mr. Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the continued growth of Biogen’s product portfolio and the development of the commercial infrastructure and approach to support the company’s key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team.

“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” said Dr. Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organization to support our increasingly robust and diverse pipeline.”

Mr. Vounatsos comes to Biogen after a 20 year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.

“I am excited to work with my new colleagues to deliver on the unique promise of the Biogen pipeline as we seek to transform the lives of patients with neurodegenerative and rare diseases around the world,” said Mr. Vounatsos. “As I move to Biogen, I am grateful to the team at Merck for the tremendous opportunities I have had over the past two decades.”

Source: Biogen

Related News

May 1, 2021

AbbVie remains one of the best buys in its sector

Life sciences

AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.

May 1, 2021

Pfizer buys infectious disease biotech Amplyx

Life sciences

Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.

May 1, 2021

Medtronic taps virtual reality ‘flight simulators’ for brain surgery, built from 3D patient scans

Life sciences

Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.

Send this to a friend